FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
ESPERITE N.V. responds to incorrect information in the press on the shareholding of its CEO Mr. Frédéric Amar. read more
Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today that 36,328 new shares were issued as a result of the exercise of stock options under the 2013 Plan for employees, consultants and management members. In view hereof, in accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers shares of which are admitted to trading on a regulated market and laying down miscellaneous provisions (the "Belgian Act"), the outstanding share capital and outstanding voting securities of the Company can be summarised as follows: read more
Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Wellington Management Group LLP. read more
Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 700,000 warrants under new warrant plans for the benefit of employees, directors and an independent consultant of the Company and its subsidiaries. read more
TiGenix NV (Euronext Brussels: TIG; the "Company"), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today that it has filed a Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission for a proposed initial public offering of its American Depository Shares ("ADSs") to be listed on the NASDAQ Global Market in the United States. The number and price of the ADSs to be offered have not yet been determined. read more
Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced its participation to the 34th edition of the annual J.P. Morgan Healthcare Conference which will be held from 11 to 15 January 2016 in San Francisco. read more
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention, today announces its financial calendar for 2016. read more
ESPERITE N.V. (Euronext: ESP, 'ESPERITE', or 'the Group') announces the issuance of a convertible loan note of EUR 925,565 to Mr. Frédéric Amar, ESPERITE's Chief Executive Officer and largest shareholder. The issuance converts a payment obligation that ESPERITE has towards Mr. Amar relating to remuneration and pre-paid investments and expenses into the note. Mr. Amar has not participated in the decision-making of the Board of Directors regarding the issuance of the note. read more
Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Abingworth Management Limited and Abingworth LLP. read more
Biocartis (Euronext Brussels: BCART), an innovative molecular diagnostics company, today announces the launch of two new products on its molecular diagnostics platform Idylla(TM). The Idylla(TM) ctBRAF Mutation Assay uses blood plasma as a sample, which is far less invasive to obtain compared to tissue biopsies. As plasma samples can repeatedly be obtained and do not require prior information on the tumour location, liquid biopsy testing opens up a range of new possibilities in terms of efficient cancer monitoring and treatment. The second assay launched by Biocartis is the tissue biopsy Idylla(TM) NRAS-BRAF-EGFR S492R Mutation Assay. This assay now allows Biocartis to offer a complete RAS-BRAF analysis that can be performed on a same-day basis, which opens up the route towards faster treatment selection ('same day results'). Both assays are initially launched as Research Use Only (RUO) products. read more